US nears deal for 500-million Pfizer doses to donate to poorer countries

The news comes on the back of the country being criticised for hoarding jabs while less wealthy countries suffer

US president Joe Biden's administration is expected to announced the deal soon.
US president Joe Biden's administration is expected to announced the deal soon. (Ken Cedeno/Reuters)

The Biden administration is negotiating with Pfizer Inc to buy an additional 500-million Covid-19 vaccines to donate globally, a person familiar with the matter said, doubling the government’s commitment to helping less-wealthy countries. 

A deal is expected to be announced in the coming days, ahead of an international Covid-19 summit Biden has called for on the sidelines of the UN General Assembly, according to the person, who spoke on condition of anonymity because the information isn’t yet public.

The Biden administration struck a nearly identical agreement with the company in August and Pfizer has been shipping those doses to international vaccine programme Covax. The programme has been slow to get doses to participant countries, leaving many less-wealthy nations having vaccinated only a tiny percentage of their populations.

The president has been clear that we will do more and more to help lead the world in getting the world vaccinated.

—  Jeff Zients, White House Covid-19 response coordinator

“The president has been clear that we will do more and more to help lead the world in getting the world vaccinated,” Jeff Zients, the White House Covid-19 response coordinator, said last week.

Details of the agreement were reported earlier by the New York Times. 

While the donations are an important diplomatic gesture by the US, broad vaccination of the global population would also help reduce the chances of mutations that could escape the vaccines protecting Americans. 

A large donation would also help deflect criticism that the US is hoarding vaccines to give its citizens booster shots, while some lower-income parts of the world wait to be inoculated. A US Food and Drug Administration (FDA) decision on whether to clear booster shots for use could happen within days, after an outside panel of experts recommended it authorise vaccines for people age 65 and above and those at high risk.

More stories like this are available on bloomberg.com

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Comment icon